Glaxosmithkline | GSK - Interest Expense On Debt


Glaxosmithkline reported GBP264.74M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Amgen USD 653M 94.99B Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Aurora Cannabis CAD 464K 234K Jun/2026
Bausch Health Companies USD 398M 2M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Canopy Growth CAD 12.68M 364K Jun/2026
Corcept Therapeutics USD 1.03B 145.32M Sep/2026
Drreddys Laboratories INR 1.06B 113M Mar/2026
Eli Lilly USD 316M 201.3M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Glaxosmithkline GBP 264.74M 72.01M Sep/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Novartis USD 468M 6M Sep/2026
Pacira USD 112.4M 108.78M Sep/2026
Perrigo USD 7.48B 124.6M Sep/2026
Pfizer USD 662M 5M Sep/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 13.94M 2.52M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 222M 65M Sep/2026
Supernus Pharmaceuticals USD 718K 1.6M Sep/2026
Takeda JPY 63.38B 466M Sep/2026
Teva Pharmaceutical Industries USD 414M 219M Sep/2026
Zoetis USD 61M 1000K Jun/2026